1. Home
  2. PHAR vs NDMO Comparison

PHAR vs NDMO Comparison

Compare PHAR & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • NDMO
  • Stock Information
  • Founded
  • PHAR 1988
  • NDMO 2019
  • Country
  • PHAR Netherlands
  • NDMO United States
  • Employees
  • PHAR N/A
  • NDMO N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • NDMO Trusts Except Educational Religious and Charitable
  • Sector
  • PHAR Health Care
  • NDMO Finance
  • Exchange
  • PHAR Nasdaq
  • NDMO Nasdaq
  • Market Cap
  • PHAR 618.3M
  • NDMO 621.8M
  • IPO Year
  • PHAR N/A
  • NDMO N/A
  • Fundamental
  • Price
  • PHAR $8.20
  • NDMO $10.53
  • Analyst Decision
  • PHAR Strong Buy
  • NDMO
  • Analyst Count
  • PHAR 3
  • NDMO 0
  • Target Price
  • PHAR $27.00
  • NDMO N/A
  • AVG Volume (30 Days)
  • PHAR 5.6K
  • NDMO 218.6K
  • Earning Date
  • PHAR 03-13-2025
  • NDMO 01-01-0001
  • Dividend Yield
  • PHAR N/A
  • NDMO 6.75%
  • EPS Growth
  • PHAR N/A
  • NDMO N/A
  • EPS
  • PHAR N/A
  • NDMO N/A
  • Revenue
  • PHAR $285,745,000.00
  • NDMO N/A
  • Revenue This Year
  • PHAR $20.08
  • NDMO N/A
  • Revenue Next Year
  • PHAR $9.22
  • NDMO N/A
  • P/E Ratio
  • PHAR N/A
  • NDMO N/A
  • Revenue Growth
  • PHAR 30.64
  • NDMO N/A
  • 52 Week Low
  • PHAR $6.65
  • NDMO $8.99
  • 52 Week High
  • PHAR $13.20
  • NDMO $11.24
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 36.29
  • NDMO 66.68
  • Support Level
  • PHAR $8.49
  • NDMO $10.33
  • Resistance Level
  • PHAR $9.35
  • NDMO $10.41
  • Average True Range (ATR)
  • PHAR 0.55
  • NDMO 0.08
  • MACD
  • PHAR -0.17
  • NDMO 0.03
  • Stochastic Oscillator
  • PHAR 12.14
  • NDMO 97.30

About PHAR Pharming Group N.V.

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.

Share on Social Networks: